Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02856451 · ClinicalTrials.gov registry record
Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 486
- Enrollment target
NCT02856451: Completed study, sponsored by Bristol-Myers Squibb.
NCT02856451 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 486 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02856451 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 486 participants
- Enrollment target
Study Summary
A case series analysis of encephalitis events reported to the Sponsor for patients treated with nivolumab to assess the risk factors and outcomes of immune-mediated encephalitis.
Primary Outcome
Time since onset of immune-mediated encephalitis to the date of outcome assessment (days) and outcomes defined as: resolved, resolving, death, physical disability (specified), cognitive disability (specified)
Interventions
- BIOLOGICAL Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 486 participants |
| Start Date | 2015-12-09 |
| Est. Completion | 2020-12-31 |
What the finished NCT02856451 record still lists
NCT02856451 is an observational study that tracks outcomes without assigning an intervention. The registered 486 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Nivolumab is the first listed.
NCT02856451 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02856451 about?
NCT02856451 is a clinical study titled "Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab". A case series analysis of encephalitis events reported to the Sponsor for patients treated with nivolumab to assess the risk factors and outcomes of immune-mediated encephalitis.
What is the current status of trial NCT02856451?
This trial is currently completed. The enrollment target is 486 participants. The study started on 2015-12-09. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT02856451?
The interventions under investigation include: Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02856451?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06420531 · 486 participants · NA
Milk And Growth In Children (MAGIC) Born Very Preterm: A Randomized Trial
- NCT07097142 · 486 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
- NCT06948435 · 487 participants · Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
- NCT06952530 · 487 participants · Phase 3
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI